SCHEMBL384281

SCHEMBL384281

c1ccc2c(c1)ccc1c3ccc(-c4ccc5c(ccc6c7ccccc7ccc56)c4)cc3ccc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 4/20 0.70
ALDH1A1 P00352 4/20 0.64
HSD17B10 Q99714 3/20 0.64
CYP1B1 Q16678 2/20 0.64
HIF1A Q16665 1/20 0.64
CYP2A6 P11509 1/20 0.60
TSHR P16473 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
CYP1A2 P05177 4/20 0.50
ERBB2 P04626 1/20 0.50
FYN P06241 1/20 0.50
MAOA P21397 1/20 0.50
ACHE P22303 1/20 0.50
AHR P35869 1/20 0.50
PAX8 Q06710 1/20 0.50
TRPM4 Q8TD43 1/20 0.50
HPGD P15428 2/20 0.48
MAPT P10636 2/20 0.48
CYP1A1 P04798 1/20 0.48
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31171128 0.97 ALDH1A1 (0.67) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL25412097 0.97 ALDH1A1 (0.67) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL383891 0.95 ALDH1A1 (0.65) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL19336426 0.91 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL19336402 0.91 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL19336404 0.91 HPRT1 (0.64) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL2723055 0.91 ALDH1A1 (0.58) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL19336383 0.90 HPRT1 (0.70) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL383544 0.90 HPRT1 (0.70) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A
SCHEMBL19336450 0.89 HPRT1 (0.61) HPRT1ALDH1A1HSD17B10CYP1B1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408729-B1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KK (JP) 2015-12-16 EP claimed
US-8580400-B2 Bichrysene compound and organic light emitting device having the compound CANON KABUSHIKI KAISHA (JP) 2013-11-12 US claimed
EP-1221460-B1 End-modified diene copolymer and rubber composition for tire tread including the same KOREA KUMHO PETROCHEM CO LTD (KR) 2012-01-25 EP claimed
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-11-10 US claimed
EP-2408729-B1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KK (JP) 2015-12-16 EP disclosed
US-8580400-B2 Bichrysene compound and organic light emitting device having the compound CANON KABUSHIKI KAISHA (JP) 2013-11-12 US disclosed
EP-2408729-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND Canon Kabushiki Kaisha (JP) 2012-01-25 EP disclosed
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-11-10 US disclosed
WO-2010107097-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110272683-A1 NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND PPOX, CRY1, OXER1 HPRT1 502/4885ALDH1A1 414/4885HSD17B10 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.